Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.75 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.67 |
| ▸ | DRD2 | P14416 | 1/20 | 0.67 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.67 |
| ▸ | LTA4H | P09960 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3216167 | 0.98 | SIGMAR1 (0.73) | SIGMAR1SLC6A3DRD2SLC6A4LTA4H | |
| SCHEMBL21416863 | 0.94 | SIGMAR1 (0.67) | SIGMAR1SLC6A3DRD2SLC6A4LTA4H | |
| SCHEMBL528725 | 0.90 | SIGMAR1 (0.69) | SIGMAR1SLC6A3DRD2SLC6A4HRH3 | |
| SCHEMBL1801297 | 0.88 | SIGMAR1 (0.68) | SIGMAR1SLC6A3DRD2SLC6A4HRH3 | |
| SCHEMBL10559365 | 0.88 | SIGMAR1 (0.68) | SIGMAR1SLC6A3DRD2SLC6A4HRH3 | |
| SCHEMBL18917601 | 0.88 | SLC6A3 (0.77) | SIGMAR1SLC6A3DRD2SLC6A4LTA4H | |
| SCHEMBL3150811 | 0.87 | SIGMAR1 (0.76) | SIGMAR1SLC6A3DRD2SLC6A4MAOA | |
| SCHEMBL13242848 | 0.86 | SIGMAR1 (0.69) | SIGMAR1SLC6A3DRD2SLC6A4HRH3 | |
| SCHEMBL3211606 | 0.86 | SIGMAR1 (0.69) | SIGMAR1SLC6A3DRD2SLC6A4MAOA | |
| SCHEMBL3218623 | 0.86 | SIGMAR1 (0.69) | SIGMAR1SLC6A3DRD2SLC6A4MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019165192-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | SAMUMED, LLC (US) | 2019-08-29 | — | — | WO | disclosed |
| US-20100048891-A1 | METASUBSTITUTED THIAZOLIDINONES, THEIR MANUFACTURE AND USE AS A DRUG | SCHULZE KLAUSE | 2010-02-25 | — | — | US | disclosed |
| US-20100048891-A1 | METASUBSTITUTED THIAZOLIDINONES, THEIR MANUFACTURE AND USE AS A DRUG | SCHULZE KLAUSE | 2010-02-25 | — | — | US | disclosed |
| US-20100048891-A1 | METASUBSTITUTED THIAZOLIDINONES, THEIR MANUFACTURE AND USE AS A DRUG | SCHULZE KLAUSE | 2010-02-25 | — | — | US | disclosed |
| US-20070015759-A1 | Metasubstituted thiazolidinones, their manufacture and use as a drug | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-18 | — | — | US | disclosed |
| US-20070015759-A1 | Metasubstituted thiazolidinones, their manufacture and use as a drug | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048891-A1 | METASUBSTITUTED THIAZOLIDINONES, THEIR MANUFACTURE AND USE AS A DRUG | PLK2, PDXK, PLK4 | SIGMAR1 3611/4885SLC6A3 4004/4885DRD2 4764/4885 |
| US-20070015759-A1 | Metasubstituted thiazolidinones, their manufacture and use as a drug | PLK4, PDXK, PLK2 | SIGMAR1 3314/4885SLC6A3 3075/4885DRD2 4618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.